Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090165 · ClinicalTrials.gov registry record · Phase 1
Ribociclib and Bicalutamide in AR+ TNBC
A Phase 1 study of Triple Negative Breast Cancer, sponsored by Kari Wisinski.
- Active
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 6
- Study locations
NCT03090165 is a Phase 1 study of Triple Negative Breast Cancer that is active but no longer recruiting, run by Kari Wisinski. The registered enrollment target is 37 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT03090165, a Phase 1 study of Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by Kari Wisinski.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open label, multi-institutional, single arm phase II trial of ribociclib in combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization or blinding is involved.
Conditions Studied
Interventions
- DRUG Bicalutamide
- DRUG ribociclib
Study Locations (6)
Illinois
- University of Illinois Cancer Center - Chicago
Michigan
- Michigan State University - Lansing
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- University of Rochester Medical Center - Rochester
Pennsylvania
- Penn State Cancer Institute - Hershey
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03090165
The ClinicalTrials.gov registry entry for NCT03090165 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Kari Wisinski, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bicalutamide is the first listed.
NCT03090165 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Michigan, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03090165 about?
NCT03090165 is a clinical study titled "Ribociclib and Bicalutamide in AR+ TNBC". This is an open label, multi-institutional, single arm phase II trial of ribociclib in combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization or blinding is involved.
What is the current status of trial NCT03090165?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2018-05-07. Estimated completion is 2026-10.
What conditions does trial NCT03090165 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer.
What interventions are being tested in trial NCT03090165?
The interventions under investigation include: Bicalutamide (DRUG), ribociclib (DRUG).
Who is sponsoring clinical trial NCT03090165?
This trial is sponsored by Kari Wisinski, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03090165 being conducted?
This trial has 6 study locations across Illinois, Michigan, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.